DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
BIBF1120 is an investigational drug.
There have been 18 clinical trials for BIBF1120. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2009.
The most common disease conditions in clinical trials are Carcinoma, Ovarian Neoplasms, and Neoplasms. The leading clinical trial sponsors are Boehringer Ingelheim, European Organisation for Research and Treatment of Cancer - EORTC, and University of Alabama at Birmingham.
Recent Clinical Trials for BIBF1120
|Ph II Nintedanib or Intravenous Ifosfamide Advanced Metastatic STS Failed on Imatinib and Sunitinib||Boehringer Ingelheim||Phase 2|
|Ph II Nintedanib or Intravenous Ifosfamide Advanced Metastatic STS Failed on Imatinib and Sunitinib||European Organisation for Research and Treatment of Cancer - EORTC||Phase 2|
|Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors||Boehringer Ingelheim||Phase 1|